CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. By Type
1.3.2. By Application
1.3.3. By End User
1.3.4. By Region
1.3.5. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. Top player positioning
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. High prevalence of life threatening diseases
3.4.1.2. Growth in awareness about blood and plasma donation
3.4.1.3. Rise in geriatric population
3.4.1.4. High adoption of blood plasma derivatives

3.4.2. Restraints

3.4.2.1. High cost of blood plasma derivatives based therapy
3.4.2.2. Risks associated with plasma derivatives

3.4.3. Opportunities

3.4.3.1. Development of better methods for plasma derivatives manufacturing
3.4.3.2. Opportunities in emerging economies

3.4.4. Impact analyses

3.5. Government regulations

3.5.1. Plasma derivatives regulations in United States and Europe

CHAPTER 4: BLOOD PLASMA DERIVATIVES MARKET, BY TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. Albumin

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. Factor VIII

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country

4.4. Factor IX

4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country

4.5. Immunoglobulin

4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country

4.6. Hyperimmune globulin

4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country

4.7. Others

4.7.1. Key market trends, growth factors and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: BLOOD PLASMA DERIVATIVES MARKET, BY APPLICATION

5.1. Overview

5.1.1. Market size and forecast (value)

5.2. Hemophilia

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. Hypogammaglobulinemia

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

5.4. Immunodeficiency diseases

5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

5.5. von Willebrand's disease (vWD)

5.5.1. Market size and forecast, by region
5.5.2. Market analysis, by country

5.6. Other application

5.6.1. Market size and forecast, by region
5.6.2. Market analysis, by country

CHAPTER 6: BLOOD PLASMA DERIVATIVES MARKET, BY END USER

6.1. Overview

6.1.1. Market size and forecast

6.2. Hospitals

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Clinics

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Other end users

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: BLOOD PLASMA DERIVATIVES MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors and opportunities
7.2.2. North America blood plasma derivatives market, by country

7.2.2.1. U.S.

7.2.2.1.1. Market size and forecast, by type
7.2.2.1.2. Market size and forecast, by application
7.2.2.1.3. Market size and forecast, by end user

7.2.2.2. Canada

7.2.2.2.1. Market size and forecast, by type
7.2.2.2.2. Market size and forecast, by application
7.2.2.2.3. Market size and forecast, by end user

7.2.2.3. Mexico

7.2.2.3.1. Market size and forecast, by type
7.2.2.3.2. Market size and forecast, by application
7.2.2.3.3. Market size and forecast, by end user

7.2.3. North America market size and forecast, by type
7.2.4. North America market size and forecast, by application
7.2.5. North America market size and forecast, by end user

7.3. Europe

7.3.1. Key market trends, growth factors and opportunities
7.3.2. Europe market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Market size and forecast, by type
7.3.2.1.2. Market size and forecast, by application
7.3.2.1.3. Market size and forecast, by end user

7.3.2.2. France

7.3.2.2.1. Market size and forecast, by type
7.3.2.2.2. Market size and forecast, by application
7.3.2.2.3. Market size and forecast, by end user

7.3.2.3. UK

7.3.2.3.1. Market size and forecast, by type
7.3.2.3.2. Market size and forecast, by application
7.3.2.3.3. Market size and forecast, by end user

7.3.2.4. Italy

7.3.2.4.1. Market size and forecast, by type
7.3.2.4.2. Market size and forecast, by application
7.3.2.4.3. Market size and forecast, by end user

7.3.2.5. Spain

7.3.2.5.1. Market size and forecast, by type
7.3.2.5.2. Market size and forecast, by application
7.3.2.5.3. Market size and forecast, by end user

7.3.2.6. Rest of Europe

7.3.2.6.1. Market size and forecast, by type
7.3.2.6.2. Market size and forecast, by application
7.3.2.6.3. Market size and forecast, by end user

7.3.3. Europe market size and forecast, by type
7.3.4. Europe market size and forecast, by application
7.3.5. Europe market size and forecast, by end user

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors and opportunities
7.4.2. Asia-Pacific market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Market size and forecast, by type
7.4.2.1.2. Market size and forecast, by application
7.4.2.1.3. Market size and forecast, by end user

7.4.2.2. China

7.4.2.2.1. Market size and forecast, by type
7.4.2.2.2. Market size and forecast, by application
7.4.2.2.3. Market size and forecast, by end user

7.4.2.3. India

7.4.2.3.1. Market size and forecast, by type
7.4.2.3.2. Market size and forecast, by application
7.4.2.3.3. Market size and forecast, by end user

7.4.2.4. Australia

7.4.2.4.1. Market size and forecast, by type
7.4.2.4.2. Market size and forecast, by application
7.4.2.4.3. Market size and forecast, by end user

7.4.2.5. South Korea

7.4.2.5.1. Market size and forecast, by type
7.4.2.5.2. Market size and forecast, by application
7.4.2.5.3. Market size and forecast, by end user

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Market size and forecast, by type
7.4.2.6.2. Market size and forecast, by application
7.4.2.6.3. Market size and forecast, by end user

7.4.3. Asia-Pacific market size and forecast, by type
7.4.4. Asia-Pacific market size and forecast, by application
7.4.5. Asia-Pacific market size and forecast, by end user

7.5. LAMEA

7.5.1. Key market trends, growth factors and opportunities
7.5.2. LAMEA market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Market size and forecast, by type
7.5.2.1.2. Market size and forecast, by application
7.5.2.1.3. Market size and forecast, by end user

7.5.2.2. Saudi Arabia

7.5.2.2.1. Market size and forecast, by type
7.5.2.2.2. Market size and forecast, by application
7.5.2.2.3. Market size and forecast, by end user

7.5.2.3. South Africa

7.5.2.3.1. Market size and forecast, by type
7.5.2.3.2. Market size and forecast, by application
7.5.2.3.3. Market size and forecast, by end user

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Market size and forecast, by type
7.5.2.4.2. Market size and forecast, by application
7.5.2.4.3. Market size and forecast, by end user

7.5.3. LAMEA market size and forecast, by type
7.5.4. LAMEA market size and forecast, by application
7.5.5. LAMEA market size and forecast, by end user

CHAPTER 8: COMPANY PROFILES

8.1. Baxter International Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance

8.2. Biotest AG

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. CSL Limited

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. Fusion Health Care Pvt. Ltd.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio

8.5. Grifols S.A.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Green Cross Holdings Corporation (Green Cross Corp.)

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments

8.7. LFB SA (LFB Biotechnologies SAS)

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments

8.8. Octapharma AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Shire Plc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. SK chemicals (SK Plasma Co., Ltd.)

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance